Soliris Market Outlook For 2026–2030 Covering Growth Drivers And Industry Trends

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Soliris Market Grow Between 2026 And 2030?

The soliris market has shown substantial expansion in recent times. Its valuation is anticipated to rise from $2030.44 million in 2025 to $2191.9 million in 2026, exhibiting a compound annual growth rate (CAGR) of 8.0%. Factors contributing to its historical growth include unmet needs in rare diseases, clinical success in pnh and ahus, regulatory orphan drug incentives, improved patient survival outcomes, and limited therapeutic alternatives.

The Soliris market size is anticipated to undergo significant expansion in the upcoming years. It is projected to achieve a valuation of $2941.58 million by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. This anticipated growth during the forecast period can be attributed to several factors, including the broadened application in additional complement mediated diseases, heightened awareness of rare conditions, progress in genetic diagnostics, increased healthcare funding directed towards orphan drugs, and effective long-term therapy adherence programs. Prominent trends expected in this period encompass the increasing adoption of complement inhibitor therapies, a heightened focus on ultra-rare diseases, the wider use of long-term biologic treatments, more prevalent genetic testing for rare disorders, and the expansion of the high-value orphan drug market.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp

What Key Drivers Are Fueling The Growth Of The Soliris Market?

The expanding occurrence of rare blood conditions is projected to boost the growth of the Soliris market in the future. These conditions are unusual ailments impacting the blood’s formation, constituents, or coagulation, including examples like hemophilia, sickle cell anemia, and thalassemia. This increased prevalence stems from better diagnostic methods, heightened awareness, and genetic along with environmental influences. Soliris functions by inhibiting the complement protein C5, thereby assisting patients with rare blood disorders by hindering excessive complement activation. This action lessens the chance of serious issues like hemolysis and organ damage, consequently enhancing overall disease management and patient results. As an illustration, data from May 2024 by the National Health Service (NHS) England, a government-funded healthcare provider in the UK, indicated that roughly 17,000 individuals in England suffer from sickle cell disease, a hereditary blood disorder, with about 250 new diagnoses each year. Consequently, the rising incidence of rare blood disorders is fueling the expansion of the Soliris market. Future expansion of the Soliris market is anticipated to be driven by increasing investments in research on rare diseases. This surge in research funding for rare diseases stems from a growing acknowledgment of unaddressed medical requirements, progress in genomics, and the promise of innovative treatments capable of enhancing patient results. Such investments benefit Soliris by deepening comprehension of conditions that lack adequate treatment, thus stimulating greater demand for efficacious therapies. For example, in July 2023, the Department of Health and Social Care, a UK government body, allocated substantial funding, comprising USD 834.20 million (£790 million) for Biomedical Research Centers, $15.06 million (£12 million) for the UK Rare Disease Research Platform, and $50.20 million (£40 million) for the NIHR BioResource, which links genetic information with clinical characteristics across 50 rare diseases to improve diagnostic and treatment development. Hence, the increasing financial commitment to rare disease research is a key factor propelling the Soliris market’s expansion.

What Are The Main Segments Within The Soliris Market Segment Structure?

The soliris market covered in this report is segmented –

1) By Type: Plasma Exchange, Plasma Infusion

2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Trends Are Influencing The Soliris Market?

The principal trend in the Soliris market involves a focus on creating biologic drugs for neuromyelitis optica spectrum disorder (NMOSD) to improve treatment selections for rare blood conditions. This signifies a major step forward in addressing NMOSD, a rare and severe autoimmune condition impacting the central nervous system, by offering an effective therapy to decrease relapses and avoid further neurological harm. For instance, in October 2023, AstraZeneca PLC, a pharmaceutical company located in the UK, secured approval for Soliris (eculizumab) from the National Medical Products Administration (NMPA) in China. This authorization is for the treatment of adult patients in China suffering from neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This makes Soliris the first and only complement inhibitor sanctioned for NMOSD therapy in China.

Who Are The Companies Participating In The Soliris Market?

Major companies operating in the soliris market are Pfizer

Get The Full Soliris Market Report:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report

Where Is The Soliris Market Most Concentrated Geographically?

North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Soliris Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report

Browse Through More Reports Similar to the Global Soliris Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Membrane Filtration Market Report 2026

https://www.thebusinessresearchcompany.com/report/membrane-filtration-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795